Our Platform

Conventional biologics like antibodies can be effective but come with high material and pharmacoeconomic costs—especially for chronic diseases requiring frequent dosing. This limits accessibility in LMICs and certain clinical applications.

GCS has developed a breakthrough platform that enhances the efficiency of biological drugs by displaying therapeutic proteins or peptides on Virus-Like Particles (VLPs). This innovative approach optimises biologic activity, whether stimulating or blocking biochemical pathways.

GCS’s platform enables the production of both VLPs and passenger proteins in a single cell, whether bacterial, yeast, or mammalian. Proof-of-concept studies confirm the system’s ability to generate viable VLPs that induce natural antibody responses in mice.

GCS’s VLP-based technology delivers greater accessibility, affordability, and efficacy, redefining the future of biologic treatments.

Creating a new generation of therapeutic vaccines

Engineered to Optimise Performance

GCS’s proprietary VLP scaffold protein and Chaperone-assisted epitope protein are expressed within a single host cell — eliminating the need for genetic fusion of the epitope protein or chemical linkage.

This approach maximises epitope density for superior immunogenicity while simplifying cell banking and downstream processing with a single-release system.

Advancing New Technologies to Overcome Complex Clinical Challenges

Four concentric circles with a glowing effect, arranged from smallest in the center to largest on the outside, against a black background.

Increased Efficiency

Traditional biologics require high drug volumes per patient, driving up costs. GCS technology drastically reduces dosage requirements (micrograms instead of milligrams), lowering production costs while maintaining efficacy.

Simple outline of a water droplet with a light blue border on a black background.

Reduced Frequency Dosing

Current biologics require dosing every 2–4 weeks with ongoing immune monitoring. GCS products offer a more efficient regimen — just 1–2 induction doses and 1–2 annual boosters — enhancing patient convenience and improving pharmaco-economics, making treatment accessible to broader populations.

A line drawing icon of gender transition with a solid circle and an arrow pointing at the circle, accompanied by a dashed circle and an arrow.

Lower Costs

High Cost of Goods Sold (CoGS) restricts market expansion and limits accessibility. Our solution minimises safety monitoring needs and reduces overall treatment costs, enabling access to emerging markets and resource-limited healthcare settings.

Therapeutic Areas

A circular loading indicator with a light blue dashed outer ring and a solid inner ring on a black background.

Inflammatory Disease

Redefining treatment approaches to modulate immune response and prevent disease progression.

Stylized blue outline of a butterfly with abstract wings on a black background.

Respiratory & Immunology

Advancing breakthrough therapies for lung and immune-related disorders.

Diagram illustrating the concept of hydrostatic pressure with forces acting on a submerged surface and fluid at different depths.

Dermatology

Developing targeted therapies to address persistent skin diseases and improve daily life.

Our Pipeline

PROGRAMME

GCS001

GCS002

GCS003

INDICATION

Senile Pruritus

Atopic Dermatitis

Inflammatory Disease

TARGET

IL-31

IL-13

Undisclosed

DISCOVERY

GCS is advancing three drug development programmes. Its leading candidate, GCS001 (for human pruritus) is in preclinical development and expected to enter clinical trials in 2027.

IN VIVO POC

PRECLINICAL

FIH